What pharmacogenomic variants are known in CYP2C19?

Key variants in CYP2C19: rs4244285 (CYP2C19*2 (splicing defect)), rs12248560 (CYP2C19*17 (-806C>T)). These variants are associated with Clopidogrel resistance, PPI dose variability, Antidepressant response.

Can PepFold design peptides targeting CYP2C19?

Yes. PepFold accepts rsIDs associated with CYP2C19, maps them to the protein structure, and generates peptide candidates. Direct-acting antiplatelet peptides bypassing CYP2C19 prodrug activation, and receptor-specific peptide antagonists for metabolism-independent efficacy.

Gene Database

CYP2C19 — Cytochrome P450 2C19

Q: What is the CYP2C19 gene?

CYP2C19 (Cytochrome P450 2C19) is located on chromosome 10q23.33. Metabolizes proton pump inhibitors, clopidogrel, certain antidepressants, and antifungals. Pharmacogenomic testing is recommended before clopidogrel therapy by CPIC guidelines.

Chromosome 10q23.33

Metabolizes proton pump inhibitors, clopidogrel, certain antidepressants, and antifungals. Pharmacogenomic testing is recommended before clopidogrel therapy by CPIC guidelines.

Pharmacogenomic Variants

rs4244285Drug response

CYP2C19*2 (splicing defect) — Clopidogrel resistance

rs12248560Drug response

CYP2C19*17 (-806C>T) — Ultra-rapid drug metabolism

Peptide Therapeutic Approaches

Direct-acting antiplatelet peptides bypassing CYP2C19 prodrug activation, and receptor-specific peptide antagonists for metabolism-independent efficacy.

Related Therapeutics

Clopidogrel (Plavix)OmeprazoleEscitalopramVoriconazole

Associated Conditions

Drug Metabolism Disorders (CYP450 Pharmacogenomics)

Genetic variation in cytochrome P450 enzymes (CYP2D6, CYP2C19, CYP2C9) creates a spectrum from ultra-rapid to poor metabolizers. This affects ~25% of all prescribed medications and is the foundation of clinical pharmacogenomics.

Analyze CYP2C19 variants with PepFold

Submit rs4244285, rs12248560 and get ranked peptide candidates in under 2 minutes.

Try Analysis View Pricing